231 related articles for article (PubMed ID: 27150086)
1. Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies.
Roopenian DC; Christianson GJ; Proetzel G; Sproule TJ
Methods Mol Biol; 2016; 1438():103-14. PubMed ID: 27150086
[TBL] [Abstract][Full Text] [Related]
2. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies.
Roopenian DC; Christianson GJ; Sproule TJ
Methods Mol Biol; 2010; 602():93-104. PubMed ID: 20012394
[TBL] [Abstract][Full Text] [Related]
3. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.
Haraya K; Tachibana T; Nanami M; Ishigai M
Xenobiotica; 2014 Dec; 44(12):1127-34. PubMed ID: 25030041
[TBL] [Abstract][Full Text] [Related]
4. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
[TBL] [Abstract][Full Text] [Related]
5. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
[TBL] [Abstract][Full Text] [Related]
6. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
[TBL] [Abstract][Full Text] [Related]
7. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.
Avery LB; Wang M; Kavosi MS; Joyce A; Kurz JC; Fan YY; Dowty ME; Zhang M; Zhang Y; Cheng A; Hua F; Jones HM; Neubert H; Polzer RJ; O'Hara DM
MAbs; 2016; 8(6):1064-78. PubMed ID: 27232760
[TBL] [Abstract][Full Text] [Related]
8. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
9. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.
Valente D; Mauriac C; Schmidt T; Focken I; Beninga J; Mackness B; Qiu H; Vicat P; Kandira A; Radošević K; Rao S; Darbyshire J; Kabiri M
MAbs; 2020; 12(1):1829337. PubMed ID: 33079615
[TBL] [Abstract][Full Text] [Related]
11. A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data.
Jones HM; Zhang Z; Jasper P; Luo H; Avery LB; King LE; Neubert H; Barton HA; Betts AM; Webster R
CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):738-747. PubMed ID: 31464379
[TBL] [Abstract][Full Text] [Related]
12. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
Proetzel G; Roopenian DC
Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
[TBL] [Abstract][Full Text] [Related]
13. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities.
Tam SH; McCarthy SG; Brosnan K; Goldberg KM; Scallon BJ
MAbs; 2013; 5(3):397-405. PubMed ID: 23549129
[TBL] [Abstract][Full Text] [Related]
14. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs.
Viuff D; Antunes F; Evans L; Cameron J; Dyrnesli H; Thue Ravn B; Stougaard M; Thiam K; Andersen B; Kjærulff S; Howard KA
J Control Release; 2016 Feb; 223():22-30. PubMed ID: 26699424
[TBL] [Abstract][Full Text] [Related]
15. Use of Cryopreserved Hepatocytes as Part of an Integrated Strategy to Characterize In Vivo Clearance for Peptide-Antibody Conjugate Inhibitors of Nav1.7 in Preclinical Species.
Foti RS; Biswas K; Aral J; Be X; Berry L; Cheng Y; Conner K; Falsey JR; Glaus C; Herberich B; Hickman D; Ikotun T; Li H; Long J; Huang L; Miranda LP; Murray J; Moyer B; Netirojjanakul C; Nixey TE; Sham K; Soto M; Tegley CM; Tran L; Wu B; Yin L; Rock DA
Drug Metab Dispos; 2019 Oct; 47(10):1111-1121. PubMed ID: 31387871
[TBL] [Abstract][Full Text] [Related]
16. Human FcRn Tissue Expression Profile and Half-Life in PBMCs.
Fan YY; Farrokhi V; Caiazzo T; Wang M; O'Hara DM; Neubert H
Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31443181
[TBL] [Abstract][Full Text] [Related]
17. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
18. Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies.
Malik PRV; Hamadeh A; Edginton AN
Pharm Res; 2022 Feb; 39(2):239-250. PubMed ID: 35118567
[TBL] [Abstract][Full Text] [Related]
19. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn
Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT
MAbs; 2021; 13(1):1893888. PubMed ID: 33691596
[TBL] [Abstract][Full Text] [Related]
20. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]